The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load

Internal Medicine

Volumn 47, Issue 5, 2008, Pages 355-360

  Kawamura, Yusuke ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Interferon; Low virus load; Sustained viral response

Indexed keywords

BETA INTERFERON; VIRUS RNA; ANTIVIRUS AGENT; RECOMBINANT INTERFERON;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NONHUMAN; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; VIRUS LOAD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 40949105234     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0454     Document Type: Article

References (26)

1. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119: 1317-1323, 2000.
2. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492, 1998.
3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy-Group (IHIT) Lancet 352: 1426-1432, 1998.
4. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351: 83-87, 1998.
5. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 26: 961-966, 1997.
6. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666-1672, 2000.
7. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34: 395-403, 2001.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment for chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
9. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response interferon-alpha therapy in hepatitis C virus infection. Hepatology 19: 1088-1094, 1994.
10. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double blind placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989.
11. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 101: 497-502, 1991.
12. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 13: 1040-1043, 1991.
13. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 21: 918-922, 1995.
14. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 113: 558-566, 1997.
15. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81, 1996.
16. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 15: 37-41, 1992.
17. Albadalejo J, Alonso R, Antinozzi P, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36: 862-865, 1998.
18. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 37: 1567-1569, 1999.
19. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes; an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520, 1994.
21. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25: 283-291, 1996.
22. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 66: 1807-1815, 2006.
23. Tabaru A, Narita R, Hiura M, Abe S, Otsuki M. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. Am J Gastroenterol 100: 862-867, 2005.
24. Sato Y, Tokuue H, Kawamura N, et al. Short-term interferon therapy for chronic hepatitis C patients with low viral load. Hepatogastroenterology 51: 968-972, 2004.
25. Fujiyama S, Chikazawa H, Honda Y, Tomita K. Effective interferon therapy for chronic hepatitis C patients with low viral loads. Hepatogastroenterology 50: 817-820, 2003.
26. Berg T, Hoffmann RM, Teuber G, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 20: 427-436, 2000.